Abstracts tagged "Biologics"

Abstract Number: 1023 • 2013 ACR/ARHP Annual Meeting
Openness To and Preference For Biologic Therapy Among Patients With Rheumatoid Arthritis Prior To Biologic Initiation: Patient and Prescriber Perspectives
Susan C. Bolge¹, Duncan Brown², Amir Goren³, Roxanne Meyer⁴ and Seth Ginsberg⁵, ¹Janssen Scientific Affairs, LLC, Horsham, PA, ²Kantar Health, New york, NY, ³Kantar Health, New York, NY, ⁴Janssen Scientific Affairs, LLC, Horsham, NY, ⁵Creaky Joints, New York, NY
Background/Purpose: Currently two modes of administration are available for biologic therapies used to treat rheumatoid arthritis (RA): subcutaneous injection (SQ) and intravenous infusion (IV). Patient…
Abstract Number: 341 • 2013 ACR/ARHP Annual Meeting
Impact Of Persistent Minimal Disease Activity On Long-Term Outcomes In Psoriatic Arthritis: Results From 5 Years Of The Long Term Extension Of a Randomized, Placebo-Controlled, Study
Arthur Kavanaugh¹, Iain B. McInnes², Philip J. Mease³, Gerald G. Krueger⁴, Dafna D. Gladman⁵, Stephen Xu⁶, Linda Tang⁷ and Katrien van Beneden⁸, ¹University of California, San Diego, La Jolla, CA, ²Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, ³Division of Rheumatology Research, Swedish Medical Center and University of Washington, Seattle, WA, ⁴School of Medicine, University of Utah, Salt Lake City, UT, ⁵University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁶Janssen Research & Development, LLC., Spring House, PA, ⁷Janssen Research & Development, LLC., Horsham, PA, ⁸Janssen Biologics Europe, Leiden, Netherlands
Impact of persistent minimal disease activity on long-term outcomes in psoriatic arthritis: Results from 5 years of the long term extension of a randomized, placebo-controlled,…
Abstract Number: 2339 • 2013 ACR/ARHP Annual Meeting
Patient Evaluations Of Subcutaneous Golimumab Delivery By Autoinjector (SmartJect®) For Treatment Of Rheumatoid Arthritis
H Schulze-Koops¹, R Giacomelli², W Samborski³, S Rednic⁴, M Herold⁵, R Yao⁶, M Govoni⁷, N Vastesaeger⁸ and HH Weng⁶, ¹University of Munich, Munich, Germany, ²Università degli Studi dell'Aquila, L'Aquila, Italy, ³Ortopedyczno-Rehabilitacyjny Szpital Kliniczny, Wielkopolskie, Poland, ⁴University of Medicine & Pharmacy, Cluj-Napoca, Romania, ⁵Internal Medicine VI, Medical University of Innsbruck, Innsbruck, Austria, ⁶Merck & Co., Inc., Whitehouse Station, NJ, ⁷MSD Italy, Rome, Italy, ⁸Merck Sharp & Dohme, Brussels, Belgium
Background/Purpose: Self-injection of subcutaneous (SC) golimumab (GLM) using an autoinjector device may be useful for patients with rheumatoid arthritis (RA), especially if they have functional…
Abstract Number: 1695 • 2013 ACR/ARHP Annual Meeting
Ustekinumab Is Effective In Inhibiting Radiographic Progression In Patients With Active Psoriatic Arthritis: Integrated Data Analysis Of Two Phase 3, Randomized, Placebo-Controlled Studies
Iain B. McInnes¹, Christopher T. Ritchlin², Proton Rahman³, Lluis Puig⁴, Alice B. Gottlieb⁵, Michael Song⁶, Bruce Randazzo⁶, Shu Li⁶, Yuhua Wang⁶, Alan M. Mendelsohn⁷ and Arthur Kavanaugh⁸, ¹Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, ²Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ³Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ⁴Universitat Autònoma de Barcelona, Barcelona, Spain, ⁵Tufts Medical Center, Boston, MA, ⁶Janssen Research & Development, LLC., Spring House, PA, ⁷Immunology, Janssen Research & Development, LLC., Spring House, PA, ⁸University of California San Diego, San Diego, CA
Background/Purpose: We describe the effect of ustekinumab (UST), an IL-12/23 p40 inhibitor, on inhibition of progression of structural damage in patients with active psoriatic arthritis…
Abstract Number: 1024 • 2013 ACR/ARHP Annual Meeting
Modeling The Benefit Risk Profiles Of a New Janus Kinase Inhibitor Tofacitinib Compared Tottumour Necrosis Factor Inhibitor Biologic Treatments Incorporating Conjoint Derived Patient Preference Weights
Michael P. Ingham¹, Shannon Cartier², Raphael J. DeHoratius³, Jack McGowan⁴ and Eric Sabot², ¹Janssen Scientific Affairs, LLC, Horsham, PA, ²Optum, Eden Prairie, MN, ³Medical Affairs, Janssen Services, LLC, Horsham, PA, ⁴Janssen Services, LLC, Horsham, PA
Background/Purpose: Tofacitinib (Tofa) was recently approved in the U.S. There are no data comparing the benefit risk profile of Tofa to tumor necrosis factor inhibitors…
Abstract Number: 320 • 2013 ACR/ARHP Annual Meeting
Sustained Improvement In Health-Related Quality Of Life, Work Productivity, Employability, and Reduced Healthcare Resource Utilization Of Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Treated With Golimumab: 5-Year Results From 3 Phase III Studies
Chenglong Han¹, Arthur Kavanaugh², Mark C. Genovese³, Benjamin Hsu⁴, Atul A. Deodhar⁵ and Elizabeth C. Hsia⁴, ¹Janssen Global Services, LLC., Malvern, PA, ²University of California, San Diego, La Jolla, CA, ³Division of Rheumatology, Stanford University, Palo Alto, CA, ⁴Janssen Research & Development, LLC., Spring House, PA, ⁵Div of Arthritis & Rheum OP-09, Oregon Health & Science University, Portland, OR
Background/Purpose: To summarize changes from baseline in health-related quality of life (HRQOL), impact of disease on work productivity, employability, and healthcare resource utilization among patients…
Abstract Number: 2348 • 2013 ACR/ARHP Annual Meeting
Long Term Safety Of Intravenous Golimumab and Comparisons With Subcutaneous Golimumab In Rheumatologic Conditions: Results From The 120-Day Safety Report Of a Phase 3 Trial Of Intravenous Golimumab
Rene Westhovens¹, Clifton O. Bingham III², Michael E. Weinblatt³, Roy Fleischmann⁴, Edward C. Keystone⁵, Elizabeth C. Hsia⁶, Benjamin Hsu⁶, Lilianne Kim⁶, Surekha Mudivarthy⁶, Michael Mack⁷, Neil Goldstein⁶, Jürgen Braun⁸, Arthur Kavanaugh⁹, Alan M. Mendelsohn¹⁰ and Jonathan Kay¹¹, ¹Rheumatology, University Hospital KU Leuven, Leuven, Belgium, ²Rheumatology, Johns Hopkins University, Baltimore, MD, ³Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁴University of Texas Southwestern Medical Center, Dallas, TX, ⁵Department of Medicine, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁶Janssen Research & Development, LLC., Spring House, PA, ⁷Biostatistics, Janssen Research & Development, LLC., Spring House, PA, ⁸PsAID taskforce, EULAR, Zurich, Switzerland, ⁹University of California San Diego, San Diego, CA, ¹⁰Immunology, Janssen Research & Development, LLC., Spring House, PA, ¹¹UMass Memorial Medical Center and University of Massachusetts Medical School, Worcester, MA
Background/Purpose: To describe safety profile of IV GLM in RA from the Ph3 GLM IV program. AE rates of interest are indirectly compared to…
Abstract Number: 1700 • 2013 ACR/ARHP Annual Meeting
Which Are The Most Common Disease Modifying Antirheumatic and Biologic Treatment Pathways For Rheumatoid Arthritis Patients?
Sofia Pedro¹, Frederick Wolfe¹, James O' Dell² and Kaleb Michaud³, ¹National Data Bank for Rheumatic Diseases, Wichita, KS, ²Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ³Rheumatology, National Data Bank for Rheumatic Diseases & University of Nebraska Medical Center, Omaha, NE
Background/Purpose: While guidelines and cost effectiveness analyses assume limited pathways for RA treatment, there is little known about what occurs in clinical practice. We sought…
Abstract Number: 1001 • 2013 ACR/ARHP Annual Meeting
Long-Term Effectiveness and Cost Per Effectively Treated Patient With Biologics Used In Rheumatoid Arthritis
Vernon F. Schabert¹, Jason Yeaw², Jonathan Korn¹, Caroleen Quach³, David J. Harrison⁴, Huifeng Yun⁵, George Joseph⁶, David H. Collier⁴ and Jeffrey R. Curtis⁷, ¹IMS Health, Alexandria, VA, ²IMS Consulting Group, Alexandria, VA, ³Public Health Policy and Management, University of North Carolina at Chapel Hill, Gillings School of Public Health, Chapel Hill, NC, ⁴Amgen Inc., Thousand Oaks, CA, ⁵Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁶Former Amgen Employee, Thousand Oaks, CA, ⁷Epidemiology, University of Alabama at Birmingham, School of Public Health, Birmingham, AL
Background/Purpose: Previous work compared one-year cost per effectively treated patient with biologics for rheumatoid arthritis (RA) using a published, claims-based algorithm.1 Longer term comparisons are…
Abstract Number: 322 • 2013 ACR/ARHP Annual Meeting
Ustekinumab Improves Physical Function, Quality Of Life, and Work Productivity Of Patients With Active Psoriatic Arthritis Who Were Methotrexate-naïve Or Previously Treated With Methotrexate Or Anti-Tumor Necrosis Factor Agent:Data From 2 Phase 3, Randomized, Placebo-Controlled Trials
Proton Rahman¹, Lluis Puig², Alice B. Gottlieb³, Arthur Kavanaugh⁴, Iain B. McInnes⁵, Christopher T. Ritchlin⁶, Shu Li⁷, Yuhua Wang⁷, Ning Zhao⁸, Rita Ganguly⁸, Michael Song⁷, Alan M. Mendelsohn⁹ and Chenglong Han⁸, ¹Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ²Universitat Autònoma de Barcelona, Barcelona, Spain, ³Tufts Medical Center, Boston, MA, ⁴University of California, San Diego, La Jolla, CA, ⁵Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, ⁶Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ⁷Janssen Research & Development, LLC., Spring House, PA, ⁸Janssen Global Services, LLC., Malvern, PA, ⁹Immunology, Janssen Research & Development, LLC., Spring House, PA
Background/Purpose: To examine the impact of ustekinumab (UST) treatment on patient reported outcomes in patients with active psoriatic arthritis (PsA) using week 24 data from…
Abstract Number: 2324 • 2013 ACR/ARHP Annual Meeting
Persistence On Biologics Is Associated With Concomitant Methotrexate Use Among Rheumatoid Arthritis Patient
Jie Zhang¹, Fenglong Xie², Elizabeth S. Delzell³, Huifeng Yun³, James Lewis⁴, Kevin Haynes⁵, Lang Chen⁶ and Jeffrey R. Curtis⁷, ¹Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ³Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁴Medicine, University of Pennsylvania, Philadelphia, PA, ⁵Clinical Epidemiology and Biostatistics, University of Pennsylvania., Philadelphia, PA, ⁶Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁷University of Alabama at Birmingham, Birmingham, AL
Persistence on Biologics is Associated with Concomitant Methotrexate Use among Rheumatoid Arthritis Patient Background/Purpose: Concomitant methotrexate (MTX) is associated with improved treatment efficacy in randomized controlled…
Abstract Number: 1607 • 2013 ACR/ARHP Annual Meeting
Two Year Follow-Up On Biologics Use In 13 Centers- Data From The International Registry For Biologics In Systemic Lupus Erythematosus
Ronald F. van Vollenhoven¹, Melinda Mild², Søren Jacobsen³, S. Bernatsky⁴, Daniel J. Wallace⁵, Sang-Cheol Bae⁶, Manuel Ramos-Casals⁷, Francisco J. García-Hernández⁸, R. Ramsey-Goldman⁹, Andrea Doria¹⁰, Marta Mosca¹¹, Michelle A. Petri¹², M Ayala-Gutiérrez¹³, J.G. Hanley¹⁴ and for The SLICC group¹⁵, ¹Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), the Karolinska Institute, Stockholm, Sweden, ²Department of medicine, Karolinska Institutet, Stockholm, Sweden, ³Department of Rheumatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, ⁴Divisions of Rheumatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada, ⁵Cedars-Sinai Medical Center, Los Angeles, CA, ⁶Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ⁷Laboratorio de Enfermedades Autoinmunes Josep Font, Hospital Clínic, Barcelona, Spain, ⁸Internal Medicine, Hospital Virgen del Rocío, Sevilla, Spain, ⁹Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, ¹⁰Rheumatology Unit - Department of Medicine, University of Padova, Padova, Italy, ¹¹Rheumatology Unit, University of Pisa, Pisa, Italy, ¹²Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ¹³Unidad de Enfermedades Autoinmunes, Servicio de Medicina Interna, Hospital Carlos Haya, Malaga, Spain, ¹⁴Division of Rheumatology, Halifax, NS, Canada, ¹⁵Department of Medicine, the Karolinska Institute, Stockholm, Sweden
Background/Purpose: Only one biologic agent has been approved for use in SLE, but some are used off-label in various settings. To obtain systematic information regarding…
Abstract Number: 874 • 2013 ACR/ARHP Annual Meeting
Sustained and Consistent Clinical Benefit With Intravenous Golimumab Therapy In Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy: Results Through 1-Year Of a Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial
Clifton O. Bingham III¹, Rene Westhovens², Alan M. Mendelsohn³, Lilianne Kim⁴, Kim Hung Lo⁴ and Michael E. Weinblatt⁵, ¹Rheumatology, Johns Hopkins University, Baltimore, MD, ²Rheumatology, University Hospital KU Leuven, Leuven, Belgium, ³Immunology, Janssen Research & Development, LLC., Spring House, PA, ⁴Janssen Research & Development, LLC., Spring House, PA, ⁵Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA
Background/Purpose: To report on sustainability and consistency of ACR component scores with intravenous (IV) golimumab (GLM) 2mg/kg+methotrexate (MTX) through wk52 in pts with active rheumatoid…
Abstract Number: 323 • 2013 ACR/ARHP Annual Meeting
Safety Of Ustekinumab From The Placebo-Controlled Periods Of Psoriatic Arthritis and Psoriasis Clinical Developmental Programs
Iain B. McInnes¹, Kim Papp², Lluis Puig³, Kristian Reich⁴, Christopher T. Ritchlin⁵, Bruce Strober⁶, Proton Rahman⁷, Arthur Kavanaugh⁸, Alan M. Mendelsohn⁹, Michael Song¹⁰, Daphne Chan¹⁰, Yaung-Kaung Shen¹⁰, Shu Li¹⁰ and Alice B. Gottlieb¹¹, ¹Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, ²Probity Research, Waterloo, ON, Canada, ³Universitat Autònoma de Barcelona, Barcelona, Spain, ⁴SCIderm Research Institute and Dermatologikum Hamburg, Hamburg, Germany, ⁵Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ⁶University of Connecticut, Farmington, CT, ⁷Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ⁸University of California, San Diego, La Jolla, CA, ⁹Immunology, Janssen Research & Development, LLC., Spring House, PA, ¹⁰Janssen Research & Development, LLC., Spring House, PA, ¹¹Tufts Medical Center, Boston, MA
Background/Purpose: To describe the short-term safety experience of UST during the double-blind, PBO-controlled portion of the PsA & PsO clinical developmental programs. Methods: Safety…
Abstract Number: 2325 • 2013 ACR/ARHP Annual Meeting
Final 5-Year Safety and Efficacy Results Of a Phase 3, Randomized, Placebo-Controlled Trial Of Golimumab In Patients With Active Rheumatoid Arthritis Despite Previous Anti-Tumor Necrosis Factor Therapy
Josef S. Smolen¹, Jonathan Kay², Robert Landewé³, Eric L. Matteson⁴, Norman B. Gaylis⁵, Jürgen Wollenhaupt⁶, Frederick T. Murphy⁷, Chenglong Han⁸, Timothy A. Gathany⁸, Stephen Xu⁹, Yiying Zhou¹⁰, Elizabeth C. Hsia⁹ and Mittie K. Doyle⁹, ¹Division of Rheumatology, Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ²Division of Rheumatology, Department of Medicine, University of Massachusetts Medical School, Worcester, MA, ³Clinical Immunology & Rheumatology, Academic Medical Center, University of Amsterdam and Atrium Medical Center, Heerlen, Netherlands, ⁴Rheumatology, Mayo Clinic, Rochester, MN, ⁵Arthritis & Rheumatic Disease Specialties, Aventura, FL, ⁶Schön Klinik Hamburg-Eilbek, Hamburg, Germany, ⁷Altoona Ctr for Clinical Research, Duncansville, PA, ⁸Janssen Global Services, LLC., Malvern, PA, ⁹Janssen Research & Development, LLC., Spring House, PA, ¹⁰Biostatistics, Janssen Research & Development, LLC., Spring House, PA
Background/Purpose: GO-AFTER was the first multicenter, randomized, placebo (PBO)-controlled trial of the safety/efficacy of an anti-TNFα agent, GLM, in pts with active RA despite prior…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.